Gabapentin
Product Images NDC 33358-154

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 33358-154). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rxchange Co., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin (Gabapentin)

Gabapentin is a medication that comes in the form of 600mg tablets. It is manufactured by InvaGen Pharmaceuticals and can be identified using the lot# and NDC code. The tablets are dispensed in a light-resistant container and should be stored at controlled room temperature. Each tablet is debossed with a "1" on the left side and "bisect on the other." The text includes information about the manufacturer, lot#, and expiration date, but no information about the medication's uses or side effects.*

FDA Label Image

D:\work\elabel\2012.10\10.25\1\figure_01.jpg (C13551d6 Figure 01)

FDA Label Image

D:\work\elabel\2012.10\10.25\1\gabapentin_25-oct-2012\figure_02.jpg (C13551d6 Figure 02)

This is a graph with the title "Weekly Mean Pain Scores" on the Y-axis and "Weeks" on the X-axis. The graph was generated from Study 1, and it shows the observed cases in the ITT (intent-to-treat) population. The medication in question is Gabapentin, and the dose administered was 3500 mg daily. The other text seems to be a mix of random characters and symbols that do not provide any useful information.*

FDA Label Image

D:\work\elabel\2012.10\10.25\1\gabapentin_25-oct-2012\figure_03.jpg (C13551d6 Figure 03)

This is a table with information related to pain scores obtained from a study. There were two treatments: "Placebo" and "Gabapentin" at two different doses - 1800 and 2400 mg/day. The table shows the mean pain scores at baseline and during 7 weeks of observation. The figure indicates a line graph of the weekly average pain scores during the study.*

FDA Label Image

D:\work\elabel\2012.10\10.25\1\gabapentin_25-oct-2012\figure_04.jpg (C13551d6 Figure 04)

FDA Label Image

D:\work\elabel\2012.10\10.25\1\gabapentin_25-oct-2012\figure_05.jpg (C13551d6 Figure 05)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.